In the rapidly evolving field of precision medicine, the integration of biomarkers into drug development has become essential. This evolution not only introduces innovative therapies but also complicates the regulatory landscape, particularly in Europe. The RAPS Workshop, “From Signal to Submission: Steering Biomarker Driven Development Through the EU Regulatory Landscape,” aims to provide regulatory professionals with the knowledge and tools needed to navigate these complexities.
Workshop Overview
This hands-on workshop is tailored for professionals in regulatory affairs, clinical development, and diagnostics, offering insights into the challenges and practices surrounding biomarker-driven drug development. Attendees will engage in interactive sessions designed to clarify the scientific and regulatory frameworks that govern this field. The goal is to enhance participants’ understanding of biomarkers from the proof-of-concept stage to pivotal clinical trials.
Understanding Biomarkers
The workshop begins with foundational knowledge about biomarkers, which are biological indicators used to assess health conditions and responses to treatments. Understanding their role in clinical development is critical, as regulators expect clear definitions and applications of biomarkers in the drug development process. Participants will learn how to effectively integrate biomarkers into clinical trial protocols while meeting regulatory expectations under the In Vitro Diagnostic Regulation (IVDR) and Clinical Trials Regulation (CTR).
Regulatory Challenges and Expectations
With the introduction of IVDR and CTR, regulatory expectations have shifted significantly. These regulations have redefined the responsibilities of sponsors in Europe, creating a need for clarity in how investigational diagnostics are utilized alongside investigational drugs. The workshop will explore the implications of these regulations, focusing on the necessary considerations for marketing authorizations of both drugs and in vitro diagnostics.
Practical Application in Clinical Trials
Through case studies, group exercises, and real-world examples, participants will delve into practical applications of IVDR rules. Discussions will include the challenges and limitations of bridging studies, assessment schedules, and trial protocols. By the end of the workshop, attendees will be equipped with actionable insights to simplify the perceived complexities of current regulations, allowing them to apply best practices in biomarker-driven clinical trials.
Future Directions in Clinical Trials
As the landscape of clinical trials continues to evolve, the workshop will also address future trends and advancements. Participants will explore how to operationalize biomarker requirements effectively, ensuring that clinical trials remain adaptable and responsive to new developments in precision medicine. This forward-looking approach is vital for maintaining relevance in an increasingly competitive field.
Target Audience
This workshop is ideal for regulatory affairs professionals, clinical development teams, diagnostic specialists, and anyone involved in the strategic management of biomarker integration in clinical trials. Participants should possess a foundational understanding of the subject matter, allowing them to engage with higher-level concepts presented during the sessions.
Pricing and Registration
To encourage participation, the workshop offers early bird pricing until March 29, 2026, with member rates at $315 and non-member rates at $370. Regular pricing will take effect from March 30 to April 29, 2026, increasing to $370 for members and $430 for non-members.
Conclusion
The RAPS Workshop on biomarker-driven development is an invaluable opportunity for professionals to enhance their understanding of regulatory requirements and operationalize best practices in clinical trials. By providing a comprehensive overview of the current landscape, the workshop enables participants to navigate future challenges with confidence and expertise.
- Key Takeaways:
- Gain clarity on biomarker roles in drug development.
- Understand IVDR and CTR regulatory expectations.
- Learn practical applications for clinical trial protocols.
- Explore future trends in precision medicine.
- Network with peers in the regulatory affairs community.
Read more → www.raps.org